Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous immunoglobulin and multiple sclerosis.

Anat Achiron1, Shmuel Miron

  • 1Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. achiron@post.tau.ac.il

Clinical Reviews in Allergy & Immunology
|January 5, 2006
PubMed
Summary

Intravenous immunoglobulin (IVIg) therapy shows promise for multiple sclerosis (MS) treatment. This review details IVIg clinical trials and its immunomodulatory mechanisms in MS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.

Neurodegenerative disease management·2026
Same author

Digital Color Vision Testing Reveals Widespread Cone Dysfunction in Multiple Sclerosis Independent of Optic Neuritis.

European neurology·2025
Same author

Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study.

Therapeutic advances in neurological disorders·2025
Same author

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study.

Neurology and therapy·2025
Same author

Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.

Frontiers in immunology·2025
Same author

Development of an interactive biosensing application for assessing finger dexterity.

Digital health·2025

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Immunomodulatory therapies are crucial for managing MS progression and symptoms.

Purpose of the Study:

  • To review current clinical trial data on Intravenous immunoglobulin (IVIg) for multiple sclerosis (MS).
  • To elucidate the proposed mechanisms of action for IVIg in modulating MS-related immunological pathways.

Main Methods:

  • Comprehensive literature search of IVIg clinical trials in MS.
  • Analysis of immunological studies detailing IVIg's effects on relevant pathways.

Main Results:

  • Summary of efficacy and safety data from recent IVIg trials in MS patients.
  • Identification of key immunological targets and modulation mechanisms of IVIg.

Conclusions:

  • IVIg represents a viable immunomodulatory treatment option for multiple sclerosis.
  • Further research into IVIg's mechanisms can optimize its therapeutic application in MS.

Related Experiment Videos